<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04135846</url>
  </required_header>
  <id_info>
    <org_study_id>1907002490</org_study_id>
    <nct_id>NCT04135846</nct_id>
  </id_info>
  <brief_title>Alpha-1 Blockade for Alcohol Use Disorder (AUD)</brief_title>
  <acronym>DOXY</acronym>
  <official_title>A Focus on Alpha-1 Blockade as a Novel Pharmacological Treatment for AUD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research is to replicate findings previously conducted in a pilot trial and
      to understand, mechanistically, the role of stress in the development of AUD
      pharmacotherapies that target noradrenergic blockade.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      16 week, between-subject, double-blind, randomized clinical trial (RCT) with doxazosin (16
      mg, or maximum tolerated dose, MTD) compared to placebo in 184 treatment seeking individuals
      with AUD
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol consumption</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of drinks per week (DPW) in naturalistic condition as measured by the timeline follow-back (TLFB)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol craving</measure>
    <time_frame>one day</time_frame>
    <description>We will measure alcohol craving using the Alcohol Craving Questionnaire (ACQ) after a cue-reactivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol craving</measure>
    <time_frame>six weeks</time_frame>
    <description>Alcohol craving in naturalistic condition will be measured using craving the Obsessive Compulsive Drinking Scale (OCDS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Alcohol Use Disorder (AUD)</condition>
  <arm_group>
    <arm_group_label>doxazosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 mg, or maximum tolerated dose (MTD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin</intervention_name>
    <description>16 mg or maximum tolerated dose (MTD)</description>
    <arm_group_label>doxazosin</arm_group_label>
    <other_name>Cardura</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 to 70 (inclusive) years of age

          -  Meet the DSM-5 criteria for AUD

          -  Desire to reduce or quit alcohol drinking

          -  Breath alcohol (BrAC) = 0.00 at each visit

          -  In good health as confirmed by medical history, physical examination and lab tests

          -  Willing to adhere to the study procedures

          -  Understand informed consent and questionnaires in English at an 8th grade level

        Exclusion Criteria:

          -  Women who are breastfeeding or /positive urine test for pregnancy

          -  CrCl&lt;60mL/min

          -  Suicide attempt in the last three months

          -  Current diagnosis of other substance disorder other than nicotine as assessed by
             self-report and urine toxicology screen at baseline

          -  Current use of medication that may interact with doxazosin and/or yohimbine

          -  History of allergy to any alpha receptor blockers

          -  Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) score ≥ 8

          -  Treatment with disulfiram, naltrexone, acamprosate, topiramate within 1 month prior to
             screening

          -  Treatment with any alpha-blocker

          -  Individuals with cardiac heat failure (CHF), as assessed by the medical history, the
             physical exam and the ECG.

          -  Baseline hypotension defined as BP reading lower than 90/60 mmHg

          -  Use of phosphodiesterase inhibitors (PDE5) erectile dysfunction medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolina L Haass-Koffler, PHARMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zoe L Brown, BA</last_name>
    <phone>401-863-6646</phone>
    <email>zoe_brown@brown.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>20923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe Brown</last_name>
      <phone>401-863-6646</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Haass-Koffler CL, Goodyear K, Zywiak WH, Magill M, Eltinge SE, Wallace PM, Long VM, Jayaram-Lindström N, Swift RM, Kenna GA, Leggio L. Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. Drug Alcohol Depend. 2017 Aug 1;177:23-28. doi: 10.1016/j.drugalcdep.2017.03.016. Epub 2017 May 16.</citation>
    <PMID>28551590</PMID>
  </results_reference>
  <results_reference>
    <citation>Kenna GA, Haass-Koffler CL, Zywiak WH, Edwards SM, Brickley MB, Swift RM, Leggio L. Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. Addict Biol. 2016 Jul;21(4):904-14. doi: 10.1111/adb.12275. Epub 2015 Jun 2.</citation>
    <PMID>26037245</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Carolina Haass-Koffler</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Alcohol use disorder, stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxazosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

